Antai Weijing Medical Secures Hundreds of Millions in Series B Funding, Files for IPO

Sep 27, 2025 18:37 CST Updated 18:37

KouTech

Developer of Microsurgical Robots

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source: Jianye Family

On September 26, KouTech, a company focusing on ultra-micro and high-precision surgical robots, announced the completion of a billion-yuan B-round financing., jointly funded by industrial capital and well-known investment institutions, with Springwood Capital serving as the exclusive financial advisor. The funds from this round will be mainly used for core technology iteration, product ecosystem enhancement, clinical registration, and international layout.

As the world's first platform enterprise focusing on small-scale refined surgical robots, KouTech originated from a precision instrument R&D team established in Tokyo, Japan in 2013. This team has served international giants such as Medtronic and Boston Scientific, accumulating over a decade of experience in precision manufacturing. After setting up operations in Shanghai in 2022, the company integrated R&D centers in the U.S. and Japan, breaking through core technologies such as the underlying components and servo systems of surgical robots, achieving 100% localization of key components and ending reliance on imports. Its general-purpose microsurgical robot and ophthalmic surgical robot have completed multiple clinical surgeries, maintaining a record of "full success, zero errors," and gaining recognition from experts at tertiary hospitals.

Currently, KouTech has built three major product matrices:General-purpose microscopic robots cover fields such as ENT, vascular surgery, etc., with an end-effector diameter of less than 3mm, capable of achieving precise 0.3mm vascular anastomosis; ophthalmic surgical robots are designed for delicate anatomical structure manipulation; gastrointestinal endoscopic robots are expected to receive certification in 2023. The company has obtained 10 patents in total, and two main products are accelerating the process of type inspection in China and registration with the U.S. FDA.

After this round of financing, the company will strengthen its "China-Japan-US" R&D network and simultaneously advance clinical applications and commercialization. The industry believes that its "platform-based technology + multi-department coverage" model is expected to reshape the market landscape of high-precision surgical robots and accelerate the globalization process of China-produced high-end medical equipment.

END

"First Stock in Cardiovascular Field" Partners with Meituan

China's First and Only: Domestically Produced Calcium Sulfate Artificial Bone Faces New Opportunities in Centralized Procurement

The First in the Industry! Once Again Disrupting the Flexible Endoscope Landscape

Stryker: "The Second Largest" Launch

Medical Device Hidden Champion, the First to Land in China

Jiangsu Ultrasound Volume-based Procurement: Mindray Leads, Vinno Breaks Through

GE Healthcare: Personnel Adjustment in China

Da Vinci, Tianzhihang: The Next Track for Surgical Robots

Orthopedic Implant Leader: All Assets to Be Sold

SoftBank, Massive Layoffs

BusinessBusiness cooperation email: qxzj@landianyiliao.com